Citation for published version:
Mulhearn, B, Li, D, McMorrow, F, Lu, H, McHugh, NJ & Tansley, SL 2022, 'A Commercial Anti-TIF1γ ELISA Is Superior to Line and Dot Blot and Should Be Considered as Part of Routine Myositis-Specific Antibody Testing', *Frontiers in Immunology*, vol. 13, 804037. https://doi.org/10.3389/fimmu.2022.804037

DOI:
10.3389/fimmu.2022.804037

Publication date:
2022

Document Version
Peer reviewed version

Link to publication

University of Bath

Alternative formats
If you require this document in an alternative format, please contact:
openaccess@bath.ac.uk

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Download date: 25. Jun. 2024

1

2

3 Brief Report

4 Title

5 A commercial anti-TIF1γ ELISA is superior to line and dot blot and 6 should be considered as part of routine myositis-specific antibody 7 testing.

8 Ben Mulhearn[1,2], Danyang Li[1], Fionnuala McMorrow[1], Hui Lu[1], Neil McHugh[1] and Sarah 9 Tansley[1,2]

10 [1]Department and Pharmacy and Pharmacology, University of Bath, Claverton Down, Bath, 11 UK, BA2 7AY

12 [2]Royal National Hospital for Rheumatic Diseases, Royal United Hospitals, Combe Park, Bath, 13 UK, BA1 3NG

14 Corresponding email address: bm765@bath.ac.uk

15

16

1) Abstract

Objectives: Anti-TIF1γ is an important autoantibody in the diagnosis of cancer-associated dermatomyositis and the most common autoantibody in juvenile onset dermatomyositis. Its reliable detection is important to instigate further investigations into underlying malignancy in adults. We previously showed that commercial assays using line and dot blots do not reliably detect anti-TIF1γ. We aimed to test a new commercial ELISA and compare with previously obtained protein immunoprecipitation.

Methods: Radio-labelled immunoprecipitation had previously been used to determine the autoantibody status of patients with immune-mediated inflammatory myopathies and several healthy controls. ELISA was undertaken on healthy control and anti-TIF1γ sera and compared to previous immunoprecipitation data.

Results: A total of 110 serum samples were analysed: 42 myositis patients with anti- TIF1γ and 68 autoantibody negative healthy control sera. Anti-TIF1γ was detected by ELISA in 41 out of 42 of the anti-TIF1γ-positive samples by immunoprecipitation, and in none of the healthy controls, giving a sensitivity of 97.6% and specificity of 100%. The false negative rate was 2%.

Conclusion: ELISA is an affordable and time-efficient method which is accurate in detecting anti-TIF1γ.

Keywords

IIMs, DM, TIF1γ, ELISA, cancer, autoantibodies, myositis

2) Introduction

The ability to detect myositis -specific and -associated antibodies (MSAs and MAAs), which can be found in the sera of 60 – 70% patients with immune-mediated inflammatory myopathies (IIMs) (1), has greatly improved the diagnosis and phenotyping of these rare diseases. Not only do they aid diagnosis, but they also guide further investigation and management (2). For instance, it is well-known that IIMs, and dermatomyositis (DM) in particular, are strongly linked with cancer, with estimates varying between 7 and 32 % (3).

Anti-transcription intermediary factor 1γ (TIF1γ) autoantibodies are found in both juvenile dermatomyositis (JDM) and adult IIMs. They are present in 7% of European adults with DM and 20 – 30% of children affected by JDM (2). Strikingly, 38 – 84% of patients adult DM patients ≥ 39 years of age who are TIF1γ-positive in both European and Japanese cohorts develop cancer in the 3 years before and after DM diagnosis (4–6). Anti-TIF1γ detection in patients with a new diagnosis of DM ≥ 39 years of age may therefore prompt a thorough investigation for the detection of cancer and reduce cancer mortality rates, making the accurate detection of anti-TIF1γ a research priority.

Currently the reference standard in the detection of MSAAs is immunoprecipitation (IP) due to its ability to detect well-described and novel autoantibodies. However, this technique is impractical for use in clinical practice owing to its expense and the length of time it takes to reach a result which usually takes a minimum of 2 – 3 weeks. For this reason, several commercially available immunoassays have become available which are low cost, easy to use, and are reported to detect an array of MSAAs. However, these immunoassays are subject to both false positives and false negatives. A number of them have recently been tested by our group and others (7,8). In particular, anti-TIF1γ was found to be particularly problematic with false negatives found in 40% samples analysed by line blot and 76% by dot blot (7). Espinosa-Ortega *et al.* (8) also found low concordance between anti-TIF1γ detected by line/dot blot and immunoprecipitation, with a Cohen's kappa of 0.56. This is likely because anti-TIF1γ frequently target a conformational epitope, meaning the tertiary antigen structure is required to remain intact to be recognised by the autoantibody (9). Whereas line and dot blot immunoassays utilise denatured antigen, enzyme-linked immunosorbent assays (ELISAs)

69 maintain the tertiary structure of the protein. Fujimoto *et al*. (10) recently tested a newly-
70 developed ELISA in a Japanese cohort of patients with a spectrum of IIMs, and found this
71 approach to be highly effective with 100% sensitivity and specificity which was a result
72 comparable to immunoprecipitation.

73 In this study, we aimed to test the same commercial ELISA kit (Medical & Biological
74 Laboratories Co. Ltd., Nagoya, Aichi, Japan) for the detection of TIF1γ autoantibodies in a
75 European cohort of adult IIM patients and compared results with samples previously analysed
76 using immunoprecipitation .

77

78 # 3) Methods

79 ## Sample selection

80 Myositis serum samples used in this study were chosen as previously described (7) from a
81 biobank of more than 3000 samples collected for research or diagnostic purposes (2,11). All
82 serum samples had previously been analysed by immunoprecipitation locally and contain at
83 least one MSAA. Twenty-five anti-TIF1γ samples had also been previously analysed by line
84 and dot blot (7). Briefly, sera were stored at -20°C prior to analysis in a facility at the University
85 of Bath. The study had ethical approval through the host Institute (University of Bath EIRA
86 reference number 17-01211). All samples from research cohorts had existing ethics in place.

87 ## ELISA

88 ELISA was performed on 5µL of diluted serum sample as per the manufacturer's instructions
89 (Medical & Biological Laboratories Co. Ltd., Nagoya, Aichi, Japan). All samples were run in
90 duplicate. Briefly, samples were thawed and diluted to a 1:101 concentration and incubated
91 on a microwell plate for 30 minutes. Wells were then incubated with a horseradish
92 peroxidase-conjugated goat anti-human IgG antibody conjugate for 30 minutes followed by a
93 TMB/peroxide substrate for 15 minutes. The reaction was terminated by 0.25 mol/L sulfuric
94 acid. All incubations took place at room temperature with 4 wash cycles between steps. The

95 absorbance of each well was read on a FLUOstar Omega microplate reader (BMG Labtech
96 Ltd., Aylesbury, Buckinghamshire, Great Britain) at 450 nm wavelength. Positive and negative
97 cut off values were calculated according to previous work described by Fujimoto *et al*. (10)
98 and expressed in arbitrary units (au).

99 Immunoprecipitation

100 Radio-immunoprecipitation had been previously undertaken as described by Tansley *et al*.
101 (7). Briefly, sera were mixed with protein-A-Sepharose beads and a 35(S)methionine
102 radiolabelled K562 cell extract, followed by fractionation by SDS-PAGE and analysis by
103 autoradiography. A characteristic doublet band at 155/140 was read as being positive for
104 TIF1γ (12).

105 Data analysis

106 Statistical analysis was undertaken using Prism 9 version 9.2.0 for macOS (GraphPad
107 Software, LLC., San Diego, CA, USA). Confidence intervals (CI) are expressed at 95%.

108

109 4) Results

110 A total of 110 serum samples were analysed, of which 42 were known to have anti-TIF1γ and
111 68 were healthy control sera. Immunoprecipitation data was held for all samples. Diagnoses
112 included DM (n=27), clinically amyopathic DM (n=4), JDM (n=5), polymyositis (n=4), and
113 overlap syndrome (n=2). All HC samples tested were autoantibody negative by
114 immunoprecipitation.

115 Commercial TIF1γ ELISA performed as well as immunoprecipitation

116 Forty-one patient samples with anti-TIF1γ tested positive by ELISA as defined by a cut-off
117 point of 32 au. None of the HC samples tested positive using this cut-off point. The remaining
118 anti-TIF1γ positive sample was just under the cut-off for positivity (30.2 au). This gives an area
119 under the ROC curve (AUC) of 0.988 (CI 0.961 – 1.000, $P < 0.0001$) which is equivalent to

120 sensitivity of 97.6% (CI 87.7% - 99.9%) and a specificity of 100% (CI 94.65% - 100%). In this
121 case, Cohen's Kappa would give a value of 1.

122 Quantitative results for the ELISA values are shown in figure 1. Briefly, the median ELISA assay
123 result for HC samples was 5.99 au. (median CI 4.74 – 7.87) and for the TIF1γ samples was
124 128.5 au. (median CI 110.4 – 135.4).



125

126 **Figure 1. TIF1γ ELISA values for 68 healthy controls and 42 TIF1γ serum samples**
127 Graph showing the relative ELISA titres for healthy control and TIF1γ samples expressed in
128 arbitrary units for each individual serum sample (circles). Dashed line represents the positive
129 cut-off point as previous described (10). All 68 healthy control (HC) samples were underneath
130 the cut-off and all but one of the 42 TIF1γ samples were above the cut-off. The TIF1γ sample
131 below the cut-off had a weak band in the 140/155 kDa region.

132 Low anti-TIF1γ ELISA titres are associated with false negative line blot results

133 Given that our group previously tested 25 anti-TIF1γ samples by line blot, we were able to
134 compare ELISA titres in this study with this data to try and understand which samples might
135 test negative by line blot. The results are shown in figure 2. All anti-TIF1γ positive samples
136 by ELISA with low titres (between 30 – 100 au.) tested negative by line blot. However, 3 out
137 of the 9 samples testing negative by line blot had high anti- TIF1γ titres (> 100 au.). The
138 difference in ELISA titres between those testing negative and positive by line blot was
139 statistically significant (P = 0.0041, two-tailed Mann-Whitney test), suggesting that lower

140 anti-TIF1γ antibody titres lead to false negative line blot results. Similarly, dot blot samples
141 returned only 7/24 (29%) true positives out of the anti-TIF1γ samples that tested positive by
142 ELISA and immunoprecipitation.



143

144 **Figure 2. Comparison of anti-TIF1γ ELISA titre and line blot result**
145 Graph showing a comparison between anti-TIF1γ ELISA titre and line blot result, as previously
146 tested by our group (7). ELISA titres are expressed in arbitrary units and calculated as per the
147 manufacturer's instructions. Lines and error bars represent median values with 95%
148 confidence intervals. The line blot results are expressed as negative (-), low positive (+),
149 moderately positive (++), and high positive (+++). The median ELISA values for negative, low
150 positive, moderately positive, and high positive results were 63.5 au., 123.5 au., 145.8 au.,
151 and 151.2 au., respectively. A two-tailed Mann Whitney test comparing ELISA titres between
152 negative (-) and positive (+, ++, +++) line blots found a statistical difference between the two
153 groups ($P = 0.0041$).

154

155 ## 5) Discussion

156 This data has shown that accurate detection of anti-TIF1γ can be achieved by ELISA and
157 confirms the findings made by Fujimoto *et al.* (10). The accuracy of detection is high and
158 would be acceptable for use in clinical practice. Compared to other cost- and time- effective
159 methods such as line and dot blot which have false negative rate of 40% - 70% (7), this data

found that ELISA has a false negative rate of 1/42 (2%). This data has also shown that anti-TIF1γ titre correlates with a positive line blot result. This result is not unexpected given that the line blot is a semi-quantitative method of detecting autoantibodies. Importantly, where ELISA was able to detect samples with low titres of anti-TIF1γ (between 30 – 100 au.), line blot was unable to do so. Line blot also failed to detect some samples with high anti-TIF1g titres (> 100 au.). Taken together, anti-TIF1γ ELISA performs better than line blot in detecting this clinically important autoantibody.

Anti-TIF1γ status by immunoprecipitation was determined by recognition of 155/140kDa bands alongside an anti-TIF1γ standard control. It remains possible that the sample negative by ELISA has an unknown autoantibody with an identical band pattern although this would seem unlikely. Furthermore, the sample produced an ELISA result just below the positive threshold and may simply be a low-titre positive. The ELISA threshold could be adjusted to reduce the likelihood of this occurring, but this is likely to lead to some false positives. The most appropriate cut-off threshold may depend on the clinical context, for example, a low false positive rate may be tolerable in patients with confirmed dermatomyositis to inform the intensity of malignancy screening.

The current study was not designed to investigate the relationship between anti-TIF1γ titres and cancer detection rates. It would, however, be useful to investigate how anti-TIF1γ titre using ELISA correlates with malignancy. Recent work by Fiorentino *et al.* (13) found anti-TIF1γ titre positively correlated with cancer detection rate in DM, ranging from 8% detection for low titres to 36% detection for high titres. Furthermore, some of our healthy control samples had low anti-TIF1γ titres just below the positive cut-off and it would be of interest to investigate if these healthy subjects had a higher malignancy rate compared to a negative anti-TIF1γ control population.

The detection of anti-TIF1γ in adult DM patients should be considered a red flag for malignancy (4–6). Accurate and timely detection of anti-TIF1γ autoantibodies is therefore vital for these patients to ensure underlying malignancy is diagnosed and treated promptly. We suggest that, when investigating IIMs, anti-TIF1γ ELISA is undertaken alongside, ANA testing and a multiplex immunoblot assay to ensure accurate detection of this important autoantibody.

190 Funding: This work was supported by funding from CureJM and the Bath Institute of
191 Rheumatic Diseases. ELISA kits were provided by MBL.

192 Disclosure statement: The authors have declared no conflicts of interest.

193 Key messages

194 1. Anti-TIF1γ is a key autoantibody in the diagnosis of cancer-associated
195 dermatomyositis and juvenile dermatomyositis
196 2. ELISA is a quick and easy method in accurately detecting anti-TIF1γ autoantibodies
197 3. Diagnosis of IIMs should include ANA immunofluorescence, line or dot blot, and anti-
198 TIF1γ ELISA

199 ## References

200 1. McHugh NJ, Tansley SL. Autoantibodies in myositis. *Nat Rev Rheumatol* (2018)
201 **14**:290–302. doi:10.1038/nrrheum.2018.56

202 2. Betteridge Z, Tansley S, Shaddick G, Chinoy H, Cooper RG, New RP, Lilleker JB,
203 Vencovsky J, Chazarain L, Danko K, et al. Frequency, mutual exclusivity and clinical
204 associations of myositis autoantibodies in a combined European cohort of idiopathic
205 inflammatory myopathy patients. *J Autoimmun* (2019) **101**:
206 doi:10.1016/j.jaut.2019.04.001

207 3. Aussy A, Boyer O, Cordel N. Dermatomyositis and immune-Mediated Necrotizing
208 Myopathies: A window on Autoimmunity and Cancer. *Front Immunol* (2017) **8**:
209 doi:10.3389/fimmu.2017.00992

210 4. Oldroyd A, Sergeant JC, New P, McHugh NJ, Betteridge Z, Lamb JA, Ollier WE, Cooper
211 RG, Chinoy H. The temporal relationship between cancer and adult onset anti-
212 transcriptional intermediary factor 1 antibody-positive dermatomyositis. *Rheumatol*
213 *(United Kingdom)* (2019) **58**: doi:10.1093/rheumatology/key357

214 5. Hida A, Yamashita T, Hosono Y, Inoue M, Kaida K, Kadoya M, Miwa Y, Yajima N,
215 Maezawa R, Arai S, et al. Anti-TIF1-γ antibody and cancer-associated myositis: A
216 clinicohistopathologic study. *Neurology* (2016) **87**:
217 doi:10.1212/WNL.0000000000002863

218 6. Fiorentino DF, Chung LS, Christopher-Stine L, Zaba L, Li S, Mammen AL, Rosen A,
219 Casciola-Rosen L. Most patients with cancer-associated dermatomyositis have
220 antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ.
221 *Arthritis Rheum* (2013) **65**: doi:10.1002/art.38093

222 7. Tansley SL, Li D, Betteridge ZE, McHugh NJ. The reliability of immunoassays to detect
223 autoantibodies in patients with myositis is dependent on autoantibody specificity.
224 *Rheumatol (United Kingdom)* (2020) **59**: doi:10.1093/rheumatology/keaa021

225 8. Espinosa-Ortega F, Holmqvist M, Alexanderson H, Storfors H, Mimori T, Lundberg IE,
226 Rönnelid J. Comparison of autoantibody specificities tested by a line blot assay and
227 immunoprecipitation-based algorithm in patients with idiopathic inflammatory
228 myopathies. *Ann Rheum Dis* (2019) **78**:858–860. doi:10.1136/ANNRHEUMDIS-2018-
229 214690

230 9. Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O'Hanlon TP, Miller FW,
231 Rider LG. A novel autoantibody to a 155-kd protein is associated with
232 dermatomyositis. *Arthritis Rheum* (2006) **54**: doi:10.1002/art.22164

233 10. Fujimoto M, Murakami A, Kurei S, Okiyama N, Kawakami A, Mishima M, Sato S,
234 Seishima M, Suda T, Mimori T, et al. Enzyme-linked immunosorbent assays for
235 detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2
236 autoantibodies in dermatomyositis. *J Dermatol Sci* (2016) **84**:
237 doi:10.1016/j.jdermsci.2016.09.013

238 11. Tansley SL, Simou S, Shaddick G, Betteridge ZE, Almeida B, Gunawardena H, Thomson
239 W, Beresford MW, Midgley A, Muntoni F, et al. Autoantibodies in juvenile-onset
240 myositis: Their diagnostic value and associated clinical phenotype in a large UK

241 cohort. *J Autoimmun* (2017) **84**: doi:10.1016/j.jaut.2017.06.007

242 12. Fujimoto M, Hamaguchi Y, Kaji K, Matsushita T, Ichimura Y, Kodera M, Ishiguro N,
243 Ueda-Hayakawa I, Asano Y, Ogawa F, et al. Myositis-specific anti-155/140
244 autoantibodies target transcription intermediary factor 1 family proteins. *Arthritis*
245 *Rheum* (2012) **64**:513–522. doi:10.1002/art.33403

246 13. Fiorentino DF, Gutierrez-Alamillo L, Hines D, Yang Q, Casciola-Rosen L. Distinct
247 dermatomyositis populations are detected with different autoantibody assay
248 platforms. *Clin Exp Rheumatol* (2019) **37**:1048–1051. Available at:
249 http://www.ncbi.nlm.nih.gov/pubmed/31376258

250